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Abstract
An unselected series of 310 colorectal carcinomas,
stratified according to microsatellite instability (MSI)
and DNA ploidy, was examined for mutations and/or
promoter hypermethylation of five components of the
WNT signaling cascade [APC, CTNNB1 (encoding h-
catenin), AXIN2, TCF4, and WISP3] and three genes
indirectly affecting this pathway [CDH1 (encoding E-
cadherin), PTEN, and TP53]. APC and TP53 mutations
were each present more often in microsatellite-stable
(MSS) tumors than in those with MSI (P < .001 for
both). We confirmed that the aneuploid MSS tumors
frequently contained TP53 mutations (P < .001),
whereas tumors with APC mutations and/or promoter
hypermethylation revealed no associations to ploidy.
Mutations in APC upstream of codons 1020 to
1169, encoding the h-catenin binding site, were found
in 15/144 mutated tumors and these patients seemed
to have poor clinical outcome (P = .096). Frameshift
mutations in AXIN2, PTEN, TCF4, and WISP3 were
found in 20%, 17%, 46%, and 28% of the MSI tumors,
respectively. More than half of the tumors with
heterozygote mutations in AXIN2 were concurrently
mutated in APC. The present study showed that more
than 90% of all samples had alteration in one or more
of the genes investigated, adding further evidence to
the vital importance of activated WNT signaling in
colorectal carcinogenesis.
Neoplasia (2005) 7, 99–108
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Introduction
The Wingless-type MMTV integration site family (WNT)
signaling cascade plays a vital role in embryogenesis, and
its deregulation is also implicated in carcinogenesis. This
pathway has mainly been uncovered through studies of
Drosophila melanogaster, but is highly conserved among
several organisms including mammalians [1]. b-Catenin is
the key component of the canonical WNT pathway and is
regulated by a multiprotein complex consisting of, among other
proteins, adenomatous polyposis coli (APC), AXIN, and glyco-
gen synthase kinase-3b (GSK-3b). In the absence of a WNT
signal, b-catenin is initially primed, followed by further phos-
phorylation, leading to proteasomal degradation [2] (Figure 1A).
In the presence of WNT stimulation, proper assembly of the
multiprotein complex is inhibited, causing accumulation of free
cytosolic b-catenin, which translocates into the nucleus, lead-
ing to transcription of downstream target genes [3] (Figure 1B).
Additionally, free cytosolic b-catenin might form a complex with
E-cadherin and a-catenin and participate in calcium-dependent
cell–cell adhesion [4].
Inactivation of the tumor-suppressor gene APC, a key
regulator of the WNT signaling pathway, is one of the earliest
transforming events observed in colorectal tumorigenesis [5].
APC is altered, by DNA sequence changes and/or by promoter
hypermethylation, in most colorectal carcinomas [6,7]. As well
as being part of the multiprotein complex targeting b-catenin for
proteolysis, APC interacts with nuclear b-catenin, reducing its
transcriptional activity and enhancing its nuclear export [8].
Furthermore, it was recently shown that APC could bind the
microtubule-associated protein EB1, suggesting a potential
effect of APC also on chromosome segregation [9,10]. A
subgroup of colorectal tumors with wild-type APC shows
oncogenic mutations in CTNNB1, the gene encoding b-catenin
[11]. These mutations mainly affect specific serine and threo-
nine residues within exon 3 of CTNNB1, the phosphorylation
sites for the kinases casein kinase 1(CK1) and GSK-3b, and
thereby impede its degradation [11]. As mentioned, b-catenin
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binds to E-cadherin and thereby influences the cell–cell
contact. Hypermethylation of the promoter region of CDH1,
the gene encoding E-cadherin, has been observed in a
subgroup of colorectal carcinomas [12], giving rise to in-
creased level of free cytosolic b-catenin. However, this
change alone is not enough to activate the WNT signaling
pathway [13,14].
Two AXIN gene family members have been identified in
humans, AXIN1 and AXIN2, and both genes show mutations
in some colorectal carcinomas with wild-type APC and
CTNNB1 [15,16]. Recently, it was observed that activation
of the WNT signaling pathway elevated the level of AXIN2,
implicating AXIN2 in a negative feedback loop controlling
WNT signaling [17,18].
Accumulation of b-catenin induces stabilization of the
tumor-suppressor protein TP53. TP53 enhances degrada-
tion of b-catenin through a negative feedback mechanism
[19]. This process was recently shown to require both CK1
and GSK-3b, indicating that TP53 induces phosphorylation
of b-catenin prior to degradation [19]. Thus, in this manner,
the mutation status of TP53 is important for the activity along
the WNT cascade.
Similarly, PTEN influences the WNT pathway by hinder-
ing the activation of integrin-linked kinase (ILK), which
inhibits GSK-3b and thereby causes accumulation of
b-catenin [20].
Two types of genomic instability have been observed in
colorectal carcinogenesis, microsatellite instability (MSI; also
known as MIN) and chromosome instability (CIN) [21]. MSI is
seen as a phenotypic trait in tumors of hereditary nonpoly-
posis cases and in a subgroup of sporadic carcinomas, both
with defect mismatch repair (MMR). However, most colorec-
tal carcinomas show losses or gains of whole, or parts of,
chromosomes and thus exhibit CIN. However, whether an
underlying instability process drives the tumor development
or not is a subject for ongoing debate [22]. Distinct pathologic
features characterize these two tumor groups (MSI and CIN).
The MSI tumors, which account for 10% to 15% of all
colorectal carcinomas, are associated with mucinous histol-
ogy, lymphocytic infiltration, diploidy, poor differentiation,
and location in the proximal colon [23]. The CIN tumors are
typically microsatellite-stable (MSS), aneuploid, and located
in the distal colon or in the rectum [21]. Furthermore,
epigenetic changes are observed in subgroups of both MSI
and CIN colorectal carcinomas [24].
Tumors with defect MMR preferentially accumulate
changes in repetitive sequences. In the WNT pathway,
genes such as TCF4,WISP3, and PTEN all harbor repetitive
sequences within their coding region, and are reported
mutated in MSI colorectal tumors [25–27].
Several genes, being part of or indirectly affecting the
WNT signaling pathway, have previously been analyzed in
colorectal tumors. However, the series has been small and
only a few components have been examined within the same
sample set. Therefore, we addressed this issue further by
mutation and methylation analyses of eight relevant genes in
a series of more than 300 Norwegian colorectal cancer
(CRC) patients. The individual gene status as well as their
combinations were evaluated in the MSI and MSS tumors
and related to clinicopathologic data including long-term
survival data.
Materials and Methods
Materials and MSI Status
A consecutive series of primary tumors from 310 CRC
patients, 158 males and 151 females, collected from seven
hospitals in the Oslo and Akershus region between 1987
and 1989 was included. The median age at diagnosis was
68.3 years (range 24–92 years). From one patient, clinical
data were missing. Surgery was given as the curative
treatment for all patients, except for a few patients with
rectal tumors who also received postoperative radiation
therapy. The survival time was recorded from the date of
surgery until death or until the last update (July 1, 1999).
Patients who died within 30 days after resection of the
tumor were censored.
Determination of the content of tumor cells in our series
has previously been described [28], ranging from 62% to
97% with a mean of 84%.
The MSI status was determined by analyzing 19 dinucle-
otide markers as well as two mononucleotide markers
(BAT25 and BAT26) [26,29,30]. Thirty-eight tumors, from
36 patients, were characterized as MSI-high (H), 33 tumors
were MSI-low (L), and 237 tumors were MSS. From four
tumors, two biopsies were analyzed and showed discordant
MSI status. Both in the present study and in previously
published studies [31], it has been shown that the MSI-L
and MSS tumors are comparable when it comes to genetic
changes as well as clinicopathologic parameters, and are,
therefore, throughout the rest of the paper, considered as
one group—the MSS group. The majority of the MSI tumors
was diploid (89%, 32/36) and located in the proximal colon
(cecum, ascendens, and right flexure) (69%, 25/36), where-
as the MSS tumors were aneuploid (68%, 134/269) and
located in the distal colon (left flexure, descendens, and
sigmoideum) or rectum (75%, 203/269). For two of the MSI
tumors and one of the MSS tumors, clinicopathologic data
were not available.
Mutation Screening of APC, TP53, and CTNNB1
We have previously investigated APC exon 15 by using
the protein truncation test (PTT) and 144/218 tumors
showed mutation in exon 15 of APC [38]. In the present
study, six additional tumors (10 biopsies) were analyzed
using the same method. Shortly, genomic DNA was ampli-
fied by polymerase chain reaction (PCR), and a T7 promoter
sequence and a mammalian initiation sequence in-frame
with a unique APC sequence were introduced. The PCR
product was subjected to coupled transcription and transla-
tion in an in vitro assay. Mutations causing premature
termination in the protein product showed altered mobility
during gel electrophoresis.
Mutations in TP53 exons 5 to 8 were previously searched
for by constant denaturant gradient electrophoresis (CDGE).
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By this protocol, we found 105 mutations in 222 tumor
samples [39]. In the present study, an additional 46 cases
were examined by temporal temperature gradient electro-
phoresis (TTGE), a method similar to CDGE but with
some modifications. The procedure and primers have been
described [40].
All aberrant migration bands detected by PTT or CDGE/
TTGE were submitted to direct sequencing on an Applied
Biosystems 373 or 377 DNA sequencer (Perkin Elmer,
Foster City, CA) (Refs. [38,39] and the present study).
CTNNB1 exons 3, 5, 6, 7, and 8 have previously been
analyzed by single-strand conformation polymorphism and
sequencing in 218 of the tumors included in this study [38].
Sequence Alterations of AXIN2
Exon 7 of AXIN2, containing four mononucleotide
repeats (A)6, (G)7, (C)5, and (C)6, was sequenced in the
MSI tumors. The following primer set was used: forward
5V-AAC CCA GTT TCT TTC CTT CT-3V and reverse 5V-
ATC CCT GCC TCA ACC TA-3V (Prof. Wanguo Liu,
personal communication) (DNA Technology AS, Aarhus,
Denmark). Standard PCR conditions and direct sequenc-
ing of purified PCR products (Microspin S300-HR columns;
Amersham Pharmacia Biotech) using the Thermo-
Sequenase cycle sequencing kit (Amersham Pharmacia
Biotech) were performed according to the manufacturer’s
protocol on an ABI PRISM 310 Genetic Analyzer (Per-
kin Elmer).
Frameshift Mutation Analysis of PTEN, TCF4, and WISP3
Two (A)6 repeats within the coding region of PTEN were
analyzed in the MSI tumors and the following primer sets
were applied: forward 5V-CCT GTG AAA TAA TAC TGG TAT
G-3V and reverse 5V-GTT TCT TCT CCC AATGAA AGT AAA
GTA CA-3V (exon 7) and forward 5V-GTG CAG ATA ATG
ACA AGGAAT A-3V and reverse 5V-GTT TCT TAC ACA TCA
CAT ACA TAC AAG TC-3V (exon 8) [32] (DNA Technology
AS). A seven-base tail (GTT TCT T) was added to each
reverse primer to avoid a plus A artifact [33]. Both forward
primers were end-labeled with a fluorochrome and the two
(A)6 repeats were amplified in multiplex PCR and analyzed
on an ABI PRISM 310 Genetic Analyzer under conditions
previously described [26]. Abnormal PCR products were
confirmed with a new PCR and the mutations were verified
by sequencing.
TCF4 with an (A)9 repeat in exon 17 and WISP3 with an
(A)9 repeat in exon 4 have formerly been analyzed [26].
However, five novel cases were included in the present study.
Methylation-Specific PCR (MSP) of APC and CDH1
Fifty-three colorectal tumor samples, consisting of
28 MSI and 25 MSS tumors, were analyzed for promoter
Figure 1. (A) In the absence of a WNT signal, a multiprotein complex consisting of -catenin, APC, AXIN, GSK-3, diversin (Div), and CK1 is formed, leading to
phosphorylation and subsequent proteosomal degradation of -catenin. (B) In the presence of a WNT signal, the multiprotein complex is not formed properly and
-catenin remains unphosphorylated and accumulates in the cytoplasm. Free cytosolic -catenin translocates into the nucleus, leading to transcription of
downstream target genes. It might also form a complex with E-cadherin and a-catenin and participate in cell – cell adhesion. The tumor-suppressor proteins TP53
and PTEN indirectly inhibit activation of the WNT signaling pathway. Components with red color are investigated in the present study. -TrCP, -transducin repeat-
containing protein; CBP, CREB-binding protein; DVL, dishevelled; FRAT, frequently rearranged in advanced T-cell lymphomas; FZD, frizzled; LRP, low-density
lipoprotein receptor– related protein.
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hypermethylation of APC and CDH1 by MSP [34]. Shortly,
MSP distinguishes unmethylated from methylated alleles of
a given gene based on sequence alterations produced by
bisulfite treatment of DNA, which converts unmethylated but
not methylated cytosine to uracil. Subsequent PCR using
primers specific to either methylated or unmethylated DNA
was then performed. Previously reported primer sets were
used for amplification of both the APC fragments [35] and the
CDH1 fragments [36] (Medprobe AS, Oslo, Norway). Tumor
DNA was treated with bisulfite and amplified as previously
described [37]. Methylation-positive samples were scored
visually by two of the authors (L.T., G.E.L.) as ‘‘+’’ (weakly
methylated) or ‘‘++’’ (heavily methylated). All samples inter-
preted as methylated were confirmed by an additional PCR.
In the association studies, only tumors showing heavily
methylation were included as positive samples.
Statistical Analyses
Pearson’s chi-square analysis or Fisher’s exact test was
used in the comparison among different groups. Cause-
specific survival analyses (death by CRC) were accom-
plished using the Kaplan-Meier method and the long rank
test was applied to determine the differences in survival.
P < .05 was considered as statistically significant. SPSS
software (SPSS, Chicago, IL) was used for all the analyses.
For hierarchical cluster analysis, the average linkage method
was used with Pearson’s correlation similarity measure. The
cluster analysis and drawing of the dendogram were per-
formed with J-Express Pro [41].
Results
APC, CTNNB1, and TP53 Mutations in MSS and
MSI Tumors
The mutation frequencies of the genes investigated are
presented in Figure 2. APC and TP53 mutations were each
present more often in theMSS tumors than in the MSI tumors
(P < .001 for both) (Table 1). All but one of the 11 MSI tumors
with mutation in APC were wild-type TP53, whereas 54%
(72/134) of the MSS tumors harbored mutations in both APC
and TP53 (P = .005). Interestingly, the majority of APC
mutations in the MSI tumors (75%) occurred outside the
mutation cluster region (MCR; codons 1286–1514); in con-
trast, 84% of the mutations in the MSS tumor group were
within the MCR (P < .001). Sixteen of 145 (11%) of the MSI
and MSS tumors with APC mutation showed two mutations
within this gene.
CTNNB1was altered in oneMSI and oneMSS tumor [38].
This MSI tumor was simultaneously altered in TCF4 and
WISP3, whereas the MSS tumor additionally showed muta-
tion in APC and TP53.
Neither APC nor TP53 mutations were associated with
CIN in the MSI tumor group (Table 2). This was also true
when the methylated APC tumors were included (P = .447).
However, a correlation between TP53 mutations and CIN
was observed in the MSS tumors (P < .001).
APC mutations residing at the 5V end of codons 1020 to
1169, encoding the b-catenin binding site (the three 15 amino
acid repeats), were seen in 17 tumors, including nine frame-
shift, six nonsense, and two missense mutations (detected
Figure 2. The mutation frequencies of the seven genes investigated in colorectal carcinomas with different MSI status. WISP3, AXIN2, and PTEN were only
analyzed in the MSI tumors. MSI, microsatellite-instabile; MSS, microsatellite-stable.
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because these two tumors also contained a frameshift
mutation located downstream of codons 1020–1169). An
early truncation in the APC protein was thus observed in
15 of the patients, and they showed a tendency to shorter
cancer-related survival than the ones with APC mutations
downstream of the codons encoding the b-catenin bind-
ing site (n = 128) (P = .096) (Figure 3). The same was seen
when the wild-type tumors (n = 78) were grouped together
with the ones with mutations downstream of codons 1020
to 1169 (P = .13).
We confirmed that patients with mutations affecting the L3
domain of TP53 (codons 236–251) had a significantly
shorter cancer-related survival versus patients with wild-type
TP53 or other mutations (P = .02). Patients with mutations
upstream of codons 1020 to 1169 in APC and/or affecting the
L3 domain of TP53 showed a tendency toward shorter
cancer-related survival than the patients with other mutations
or no mutations in these genes (P = .088). A synergistic
effect of early APC mutation and those affecting the zinc
binding domain (L3) of TP53 was not observed; however,
only four tumors contained both mutations.
Frameshift Mutations of ‘‘WNT Genes’’ in MSI Tumors
AXIN2, PTEN, TCF4, and WISP3 all contain mononucle-
otide repeats within their coding region and are thus prone for
mutations in the MSI tumors. Frameshift mutations within
AXIN2, PTEN, TCF4, andWISP3 were found in 7/35 (20%),
6/36 (17%), 17/37 (46%), and 10/36 (28%) among the MSI
tumors, respectively. TCF4 was exclusively changed in the
MSI tumors (P < .001).
Mutation in exon 7 of AXIN2 was observed in seven
MSI tumors, and all were heterozygous mutations. Three
tumors contained an insertion of one G in the (G)7 repeat,
two tumors showed deletion of one G in the (G)7 repeat, one
tumor harbored deletion of one C in the (C)6 repeat, and,
finally, one tumor had deletion of one A in the (A)6 repeat. In
one primary tumor, two biopsies were analyzed, but a
different AXIN2 status was determined, and this tumor was
therefore excluded from Figure 2. Interestingly, all three
tumors with insertion of one G and one tumor with deletion
of one G in the (G)7 repeat were concurrently mutated inAPC
(Figure 4). Three of these tumors showed the same APC
mutation, insertion of one A (GAA–GAAA) at codon 1554,
whereas in the last tumor, the APC mutation could not be
verified by sequencing.
Six MSI tumors were mutated in PTEN. The frameshift
mutations were evenly distributed between exons 7 and 8.
One primary tumor was excluded because three biopsies
were analyzed and discordant PTEN status was found.
Biallelic mutations were seen in one of the tumors, whereas
the others showed monoallelic mutations. In the tumor with
homozygous mutation of PTEN, none of the other analyzed
genes was changed.
Hypermethylation of APC and CDH1 in MSS and
MSI Tumors
Heavy methylation of the promoter region of APC
was found in 10 MSI tumors (10/28, 36%) and two were
concurrently mutated in APC. On the contrary, in the MSS
group, 7/25 (28%) showed hypermethylation of APC and five
of these were simultaneously mutated in APC (P = .06). The
promoter region of CDH1 was hypermethylated in 39% (11/
28) and 42% (10/24) of the MSI and MSS tumors, respec-
tively, and within both groups, alteration of APC (mutation
and/or methylation) was observed in more than 60% of the
cases.
Cluster Analysis of WNT Components in MSI Tumors
Hierarchical cluster analysis was performed on the MSI
tumors (Figure 5). Only tumors informative in at least six
of the nine loci investigated were included in the analysis
(n = 34). Mutations in APC occurred most frequently
together with TCF4 mutations, and a subset of these
tumors also contained mutations in AXIN2. APC was the
sole WNT component changed in one MSI tumor (1193), as
Table 1. APC and TP53 Status in Correlation with MSI Status.
APC and TP53 Status MSI (n = 38) MSS (n = 269) P
APC *
mut (n = 145) 11 134 <.001
wt (n = 75) 22 53
TP53 y
mut (n = 129) 7 122 <.001
wt (n = 135) 30 105
APC and TP53 z
mut and mut (n = 73) 1 72 .005
mut and wt (n = 72) 10 62
MSI, microsatellite-instable; MSS, microsatellite-stable; mut, mutation; wt,
wild type.
*APC mutation status was not known in 4 MSI and 82 MSS tumors; from one
MSI tumor, a different APC status was detected in the three biopsies
analyzed.
yTP53 mutation status was not determined in 42 MSS tumors; in one MSI
tumor two, biopsies showed discordant TP53 status.
zOnly tumors with mutation in APC were included in the table.
Table 2. APC and TP53 Mutations in Relation to MSI Status and DNA
Content.
MSI Status
and DNA
Content
APC
mut*
APC wt P TP53
muty
TP53 wt P
MSI (n = 36)
CSz 9 21 ns§ 5 28 ns
CIN§ 1 0 0 2
MSS (n = 269)
CS 59 26 ns 37 57 <.001
CIN 75 27 85 48
MSI, microsatellite-instable; MSS, microsatellite-stable; mut, mutation; wt,
wild type; ns, not significant.
*APC mutation status was not known in 4 MSI and 82 MSS tumors; from one
MSI tumor, a different APC status was detected in the three biopsies
analyzed.
yTP53 mutation status was not determined in 42 MSS tumors; in one MSI
tumor, two biopsies showed discordant TP53 status.
zCS, chromosome-stable (2n [flow cytometry; <1.1] and 4n [flow cytometry;
1.9–2.1]).
§CIN, chromosome-instable (all other DNA content).
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was AXIN2 in another tumor (984). Tumors showing hyper-
methylation of APC additionally harbored epigenetic
changes of CDH1. The genes directly involved in the
WNT signaling pathway (APC, TCF4, AXIN2, CTNNB1,
and WISP3) clustered together, whereas PTEN was most
different from all the other components. From three primary
tumors (1132, 1141, and 1268), two or more biopsies were
analyzed and they showed deviating molecular results and
therefore did not cluster together. This was also observed
for one patient, in which two primary tumors were included
(1388A and 1388C).
We did not observe any differences in cancer-related
survival between patients with MSI tumors harboring alter-
ations in three or more of the seven WNT components
analyzed (APC, CTNNB1, AXIN2, TCF4, WISP3, PTEN,
and TP53) (n = 6) compared to patients with MSI tumors
containing alterations in less than three of the components
(n = 28) (P = .66).
As many as 90% (279/310) of the tumors included in the
present study showed alteration in one or more of the eight
WNT genes investigated.
Discussion
The canonical WNT signaling pathway is activated in the
vast majority of colorectal tumors. APC is one of the key
components of this pathway and dysfunction of APC is
observed in familial polyposis coli (FAP) patients and in
most cases of sporadic colorectal tumors [6]. Inactivation of
APC leads to accumulation of b-catenin in the cytoplasm
and nucleus, and thereby activation of WNT signaling.
Although several of the WNT components have been
reported altered in CRC as well as in other malignancies,
to our knowledge, none has studied the interaction of
multiple components within the same tumor series.
The frequency and distribution of mutations in AXIN2
were comparable with two previously published studies
[16,42]. Insertion of one G in the (G)7 repeat predicted a
stop at amino acid 706, whereas all the other mutations
predicted stop at amino acid 688 (http://us.expasy.org/tools/
dna.html). Although the mutations gave rise to stop at
different places in the AXIN2 protein, they all led to elimina-
tion of the DIX (dishevelled and AXIN) domain (amino acids
761–843), a domain necessary for homo-oligomerization
and thus essential for the inhibitory effect of AXIN2 in the
WNT pathway [43] (Figure 6). In a previously published
study, tumors harboring mutations in AXIN2 were wild-type
APC and CTNNB1 [16]. However, in our study, 4/7 (57%)
tumors with AXIN2 mutation also harbored mutation in APC.
The same was observed for one of the tumors analyzed by
Domingo et al. [42]. Among the remaining three tumors with
mutation in AXIN2 in the present study, two harbored muta-
tions in either TP53 or TCF4. This suggests that heterozy-
gous mutation of AXIN2 alone is not sufficient to activate the
WNT signaling pathway. Tumors with heterozygous muta-
tion of AXIN2 express one wild-type allele that might retain
the inhibitory effect of AXIN2; or AXIN1, the homologue of
AXIN2, might substitute for the functions of mutated AXIN2.
Therefore, other components of the WNT signaling pathway
need to be altered in order to fully activate this pathway.
Neither of the two previous studies of AXIN2 analyzed
several components of the WNT signaling pathway in the
same tumor series [16,42].
Germline mutations in PTEN have been found in Cow-
den’s syndrome and in a few patients with juvenile polyposis
Figure 3. Patients with tumors containing APC mutation upstream of codons
1020 to 1169, encoding the -catenin binding site (the three 15 amino acid
repeats), showed a shorter cancer-related survival than those with tumors
harboring mutations downstream of codons 1020 to 1169.
Figure 4. AXIN2 and APC mutations within the same MSI colorectal
carcinoma (sample 988). Direct sequencing identified an insertion of one G in
the (G)7 repeat of AXIN2. PTT and sequencing were used to recognize an
insertion of one A at codon 1554 of APC.
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syndrome—both syndromes associated with an increased
risk of CRC [6]. Somatic mutations have also been reported
in about 15% to 20% of colorectal carcinomas [27,44–46].
PTEN inhibits the activities of phosphatidylinositol-3 kinase
(PI-3K) and thus the PI-3K–dependent signaling pathway
regulating cell survival and growth. Recently, PTEN and
PI-3K were shown to influence the WNT signaling pathway
[20]. In PTEN-null prostate cancer, cell lines activated PI-
3K–phosphorylated ILK, which subsequently inhibited GSK-
3b and led to accumulation of nuclear b-catenin and
increased expression of cyclin D1. Reexpression of PTEN
increased phosphorylation and degradation of b-catenin [20].
PTEN thus works as a negative regulator of WNT signaling
[44,45]. Recently, Nassif et al. [46] showed that PTEN
mutations were also present in a subgroup of sporadic
MSS colorectal tumors and that biallelic inactivation (two
mutations or mutation and loss of heterozygosity) occurred in
more than half of these cases, leading to absence of PTEN
expression. Epigenetic inactivation of PTEN has also been
suggested as a contributing mechanism in colorectal carci-
nogenesis [44,46]. Overall, these findings indicate that inac-
tivation of PTEN is important during development of both
MSI and MSS colorectal tumors, wherein activation of the
WNT signaling pathway seems to be one of the central
mechanisms. The frequency and distribution of PTEN muta-
tions in the present series are in line with previous reports
[27,44,45]. Interestingly, in the tumor with homozygous
mutation of PTEN, none of the other WNT components
was altered, indicating that this change alone might be
sufficient to activate this pathway.
In contrast to the MSS tumors, the MSI tumors with APC
mutation were wild-type TP53; however, the majority of
these tumors had changes in other WNT components that
might partly substitute for the effect of a mutation in TP53.
Interestingly, all but one of the MSI tumors with APC muta-
tion outside the MCR showed mutation downstream of
the MCR (usually in the hot spot codon 1554), whereas in
the subgroup of MSS tumors harboring mutation outside the
MCR, the majority of these mutations occurred upstream of
the MCR. All MSI tumors with mutation downstream of MCR
also had mutations in other WNT components, most fre-
quently within TCF4 and AXIN2, whereas the MSI tumor with
APCmutation upstream of the MCR did not show changes in
any of the other WNT components analyzed. This might
indicate that tumors with mutation downstream of the MCR
have kept more of the b-catenin binding and degradation site
(codons 1342–2075) and therefore require additional muta-
tions in order to activate the WNT pathway. On the other
hand, all except two of the tumors (both MSI and MSS) with
mutation upstream of the MCR had lost all b-catenin binding
(codons 1020–1169) and downregulation sites (codons
1342–2075) [6], suggesting accumulation of b-catenin in
the nucleus and transcription of WNT target genes. APC
mutations upstream of codons 1020 to 1169, although
heterozygous, might thus alone be sufficient to activate the
WNT cascade. The significance of this early mutation is
further strengthened by the worse clinical outcome observed
in these patients compared to the patients with other APC
Figure 5. Hierarchical cluster analysis of the MSI tumors using average
linkage and Pearson’s correlation. The samples are given in the right
dendogram, and each analyzed gene is depicted at the top of the dendogram.
Each column represents the alteration in one gene over all tumor samples,
whereas each row represents the changes in each tumor. Only MSI tumors
(n = 34) informative in six of the nine loci investigated were included. From
three primary tumors, two or more biopsies were analyzed. Black box,
mutation; white box, wild-type; grey box, not determined. Mut, mutation; met,
methylation.
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mutations or the ones with wild-type APC. Even distribution
of TP53 L3 domain mutations, which by itself is associated
with shorter cancer-related survival, was present in the two
APC mutation groups and therefore did not influence the
result. The same was true for MSI, which occurred in
approximately 7% of each of these tumor groups.
APC has been suggested to control proper chromosome
segregation in mouse embryonic stem cells, and APC muta-
tions in these cells have led to karyotypic alterations termed
CIN [9,10]. However, by more thorough examination of these
mouse cells, polyploidization of the whole genome, rather
than losses and gains of one or a few chromosomes, was
observed [9]. Furthermore, well-characterized human colon
cancer cell lines harboring APC mutations exhibit a stable
karyotype after more than thousands of cell divisions [47].
Within our tumor material, no association between APC
mutation and CIN was observed, supporting the latter obser-
vation; however, an association between APC mutation and
tetraploidy (1.9–2.1 by flow cytometry) was not found. On
the other hand, an association between TP53mutations and
CIN was seen, in line with our previous reports as well
as those of others [30,39,48].
The presence of APC mutation was equally distributed
between the MSS tumors and the MSI tumors without hyper-
methylation of APC. However, among the hypermethylated
tumors, a skewed distribution of APC mutations within these
two groups was present. One explanation is that both alleles
are inactivated by hypermethylation in the MSI tumors and
therefore an additional mutation in APC is not required to
fully inactivate the protein; whereas only one allele is inacti-
vated by epigenetic mechanisms in the MSS tumors and
therefore an additional mutation is necessary.
Figure 6. (A) The coding region of AXIN2 and corresponding domains and binding sites. (B) The consequence of the different AXIN2 mutations in relation to
mutations in APC, TP53, and TCF4. Insertion of one G in the (G)7 repeat of AXIN2 predicted stop at amino acid 706, whereas all the other mutations predicted stop
at amino acid 688. In both situations, loss of the DIX domain was observed. Four tumors with AXIN2 mutations were concurrently mutated in APC.
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It has been suggested that lost or reduced expression of
E-cadherin alone is not sufficient to activate the WNT sig-
naling pathway [13,14]. The increased level of free cytosolic
b-catenin will rapidly be removed by an intact degradation
system. However, if components of the degradation complex
are also affected, b-catenin will accumulate and the WNT
pathway will be activated. In our study, hypermethylation of
CDH1 was associated with alteration of APC, thus support-
ing the latter view.
The majority of the mutations detected in the WNT genes
was monoallelic, and usually two or more components were
mutated within the same tumor, thereby affecting the WNT
pathway at different levels and jointly contributing to the
induction of its activation. For instance, frameshift mutations
in TCF4, leading to a truncated protein with reduced capa-
bility to bind a transcriptional repressor [49], occurred in
tumors with an impaired b-catenin degradation system
(mutation in APC and AXIN2). PTEN and TP53 influence
the WNT signaling pathway in a more indirect manner, and
this may explain why they do not cluster together with the
mutated WNT components. These two proteins are both
involved in several different signaling pathways [50,51]
and mutations within these genes may lead to cellular
transformation without complete activation of the WNT sig-
naling pathway.
Molecular studies have shown that nearly all colorectal
tumors contain an activating mutation of the WNT signaling
pathway [5], and this is in agreement with our findings. In
the few cases in our series without any changes in the
examined genes, other WNT components may be altered.
One candidate is AXIN1, which has been reported mutated
in a subgroup of MSI colorectal tumors [15]. Another
candidate is the PP2R1B gene, encoding the b-isoform of
the A subunit of the holoenzyme PP2A, reported mutated in
15% of colorectal tumors [52]. In Xenopus, PP2A is present
in the b-catenin degradation complex, where it might de-
phosphorylate and activate GSK-3b, leading to degrada-
tion of b-catenin and inhibition of the WNT signaling
pathway [53]. WNT components upstream of the b-catenin
degradation complex may also harbor alterations so far not
described, however.
Knowledge about molecular mechanisms leading to
activation of the WNT signaling pathway is increasing, as
well as the information on how this activated pathway
contributes to the initiation of colorectal carcinogenesis
[5]. We and others clearly demonstrate that this pathway
is turned on in nearly all colorectal carcinomas, thus
pinpointing the necessity of WNT activation during devel-
opment of a colorectal tumor.
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